Joel Finlayson is now an Adjunct Partner and LP with iGan. He supports the Investment Committee and several portfolio companies after having stepped back from day-to-day Partner responsibilities in March when he accepted a role with Accenture as a Managing Director for Healthcare. Joel joined iGan as a Partner in 2017 and helped refine and deliver on iGan’s investment thesis in digital health and connected medical technologies. In this time he was also seconded to Think Research, a portfolio company, to support with strategy & growth and stayed with that company until its listing on the TSX Venture exchange in December 2020.
Joel joined iGan with 20 years of strategy consulting & investing experience in healthcare & technology. He was the Co-Founder & Managing Director of WellNovation a family-office funded healthcare incubator based in Riyadh & Dubai that established businesses in diagnostic imaging, primary care and medical education. Previously, Joel was the Middle East Healthcare Partner with PwC and the leader of the firm’s Healthcare Strategy Practice. There he worked closely with regional governments on the comprehensive restructuring of national healthcare systems. Joel moved to the Middle East with MONITOR Group where he was an Associate Partner & General Manager after working with MONITOR in Canada and the US for many years.
Joel is an Associate of the Creative Destruction Lab in Toronto, a Board Director of the Royal College of Physicians & Surgeons of Canada (International) and serves on the boards of MedChart and SomaDetect, two iGan portfolio companies.
Joel holds an MBA from Cambridge University in the UK, an undergraduate degree in Politics & Economics from Dalhousie University in Canada, and has completed executive healthcare programs at Berkeley School of Public Health and INSEAD.